• Register
  • Login

European Journal of Molecular & Clinical Medicine

  • Home
  • Browse
    • Current Issue
    • By Issue
    • By Subject
    • Keyword Index
    • Author Index
    • Indexing Databases XML
  • Journal Info
    • About Journal
    • Aims and Scope
    • Editorial Board
    • Publication Ethics
    • Indexing and Abstracting
    • Peer Review Process
    • News
  • Guide for Authors
  • Submit Manuscript
  • Contact Us
Advanced Search

Notice

As part of Open Journals’ initiatives, we create website for scholarly open access journals. If you are responsible for this journal and would like to know more about how to use the editorial system, please visit our website at https://ejournalplus.com or
send us an email to info@ejournalplus.com

We will contact you soon

  1. Home
  2. Volume 9, Issue 7
  3. Author

Online ISSN: 2515-8260

Volume9, Issue7

Diagnostic Utility of CD56, CK19 and p63 in Differentiation of Papillary Carcinoma Thyroid from Follicular Neoplasms

    Ruby Sahu, Minakshi Bhardwaj, C.K. Durga, D.S. Chauhan, Arvind Ahuja

European Journal of Molecular & Clinical Medicine, 2022, Volume 9, Issue 7, Pages 2187-2193

  • Show Article
  • Download
  • Cite
  • Statistics
  • Share

Abstract

Background: Papillary thyroid carcinoma is the commonest malignancy of thyroid. The diagnosis of such lesions can be easily rendered by using standard histological criteria. However, distinguishing the follicular variant of papillary carcinomafrom other follicular neoplasmsis difficult. Objectives:  In this study we investigated the role of CD56, CK19 and p63 in differentiating papillary carcinoma thyroid from follicular neoplasms.
Materials and Methods: The immunohistochemical expression of CD56, CK19 and p63 was evaluated individually and in combinations in 30 samples of thyroid lesions. Thyroid lesions included: 26 Papillary carcinoma thyroid [classic papillary carcinoma (21) and follicular variant of papillary carcinoma thyroid (5)] and 4 cases of follicular carcinoma.
Results: CD56 was found to be 100% sensitive and 84.62% specific in differentiating papillary thyroid carcinoma from follicular neoplasms. p63 was 50% sensitive and 57.69% specific in differentiating papillary thyroid carcinoma from follicular carcinoma.CD56 and CK19 were more specific than p63 in differentiation of Papillary carcinoma thyroid from follicular neoplasms. (p=0.039,0.001 respectively).Combination of all the three markers showed sensitivity and specificity of  100% and 53.85% respectively.
Conclusion: Combined utility of CD56, CK19 and p63 is helpful in diagnosing papillary thyroid carcinoma including follicular variant and it’s differentiation from follicular carcinoma.
Keywords:
    Papillary thyroid carcinoma follicular carcinoma CD56 CK19 and p63
  • PDF (481 K)
  • XML
(2022). Diagnostic Utility of CD56, CK19 and p63 in Differentiation of Papillary Carcinoma Thyroid from Follicular Neoplasms. European Journal of Molecular & Clinical Medicine, 9(7), 2187-2193.
Ruby Sahu, Minakshi Bhardwaj, C.K. Durga, D.S. Chauhan, Arvind Ahuja. "Diagnostic Utility of CD56, CK19 and p63 in Differentiation of Papillary Carcinoma Thyroid from Follicular Neoplasms". European Journal of Molecular & Clinical Medicine, 9, 7, 2022, 2187-2193.
(2022). 'Diagnostic Utility of CD56, CK19 and p63 in Differentiation of Papillary Carcinoma Thyroid from Follicular Neoplasms', European Journal of Molecular & Clinical Medicine, 9(7), pp. 2187-2193.
Diagnostic Utility of CD56, CK19 and p63 in Differentiation of Papillary Carcinoma Thyroid from Follicular Neoplasms. European Journal of Molecular & Clinical Medicine, 2022; 9(7): 2187-2193.
  • RIS
  • EndNote
  • BibTeX
  • APA
  • MLA
  • Harvard
  • Vancouver
  • Article View: 62
  • PDF Download: 96
  • LinkedIn
  • Twitter
  • Facebook
  • Google
  • Telegram
Journal Information

Publisher:

Email:  editor.ejmcm21@gmail.com

  • Home
  • Glossary
  • News
  • Aims and Scope
  • Privacy Policy
  • Sitemap

 

For Special Issue Proposal : editor.ejmcm21@gmail.com

This journal is licensed under a Creative Commons Attribution 4.0 International (CC-BY 4.0)

Powered by eJournalPlus